Antihyperglycemic medication use was assessed on the drug class level including metformin, sulfonylureas, thiazolidinediones, SGLT2i
by N Katsiki 2024 Cited by 45empagliflozin, all SGLT2i, and non-SGLT2i antidiabetic drugs, respectively. [11] Garvey WT, Van Gaal L, Leiter LA, Vijapurkar U, List J, Cuddihy R, et al.
Exception: SToP any SGLT2i agents 2 days before procedure or surgery unless you are having a minor procedure. SGLT2i agents include: Forxiga, Glyxambi
In general, the distribution of each indicator was similar in SGLT2i-related AEs and IMEs. For SGLT2i-related IMEs, monotherapy (94.99%) accounted for a much larger proportion than combination therapy, with canagliflozin constituting nearly half (48.26%). The vast majority of reports cited SGLT2i as the primary suspect drug (94.55%).
Recommendation for addition of an SGLT2i (or GLP-1RA where SGLT2i is not tolerated or contraindicated) to other glucose lowering medication(s) in adults
Four SGLT2i are currently commercially available in many countries: canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin. SGLT2i reduce glycated
Recommendation for addition of an SGLT2i (or GLP-1RA where SGLT2i is not tolerated or contraindicated) to other glucose lowering medication(s) in adults
Sodium/glucose cotransporter-2 inhibitors (SGLT2i) are a new type of glucose-lowering drug that can reduce blood glucose by inhibiting its reabsorption in proximal tubules and by promoting urinary glucose excretion. SGLT2i are widely used in the clinical treatment of type 2 diabetes mellitus (T2DM). In recent studies, SGLT2i were found to not only reduce blood glucose but also protect the
Recommendation for addition of an SGLT2i (or GLP-1RA where SGLT2i is not tolerated or contraindicated) to other glucose lowering medication(s) in adults
Comments